亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Evaluating the value of neoadjuvant radiotherapy in patients with breast cancer

医学 放射治疗 倾向得分匹配 乳腺癌 肿瘤科 内科学 逻辑回归 队列 回顾性队列研究 阶段(地层学) 总体生存率 多元分析 辅助放疗 新辅助治疗 人口 队列研究 保乳手术 佐剂 癌症 生存分析 化疗 放射外科 外科 辅助治疗 T级 辅助化疗 存活率 人口研究
作者
Wenyan Dong,Yao Pan,Wu Zz,Dengfeng Wu
出处
期刊:Discover Oncology [Springer Nature]
标识
DOI:10.1007/s12672-026-05466-3
摘要

BACKGROUND: The benefits of preoperative neoadjuvant radiotherapy (NART) for breast cancer are not conclusive and there are no well-established guidelines for NART. We aimed to analyze the difference in survival benefit between NART and postoperative adjuvant radiotherapy (PORT) and screening patients who are suitable for NART. METHODS: A retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) from 2010 to 2021 was performed. We comprehensively assessed trends in the management of NART in the population during the past decade. The factors associated with NART were then explored using logistic regression. We also compared BC patients with preoperative neoadjuvant radiotherapy (NART) or postoperative adjuvant radiotherapy (PORT) for overall survival (OS) and breast cancer-specific survival (BCSS) after propensity score matching (PSM), and attempted to identify precise subgroups of patients that could benefit from NART. RESULTS: 1785 patients receiving NART were identified from a total of 274,199 patients between 2010 and 2021, with a median follow-up time of around 58 months. NART utilization in higher tumor stages shows a slight upward trend. Based on the multivariate logistic regression model, age more than 50 years old (OR = 0.86; 95% CI 0.78 to 0.94), stage II-III (II: OR = 1.49; 95% CI 1.28 to 1.74 III: OR = 2.44; 95% CI 1.98 to 3.00), T4 (OR = 1.52; 95% CI 1.25 to 1.84), HR-/HER2- (OR = 0.8; 95% CI 0.70 to 0.92) were independently correlated with NART. PORT was significantly associated with better survival (P < 0.001, HR = 0.6709; 95% CI 0.5898-0.7630 for OS) after propensity score matching (PSM). Subgroup analyses showed that for patients of HR-/HER2- subtype, AJCC stage I category or patients receiving breast-conserving surgery (BCS), NART and PORT resulted in similar OS and BCSS. We also identified risk factors for second primary malignancies development after breast cancer and found that NART were related to the lower risk of developing second primary malignancies following breast cancer. CONCLUSION: Over time, an increasing number of breast cancer patients received NART. We cannot affirm that NART is as effective as PORT in the treatment of BC, however we can consider NART as an alternative option in some contexts such as patients of AJCC stage I category and patients receiving BCS, given its potential advantages of reducing second primary malignancies risk.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ的应助被佳莉采纳,获得10
刚刚
c_phoebe完成签到,获得积分10
7秒前
13秒前
15秒前
31秒前
懵懂的念波完成签到,获得积分10
31秒前
33秒前
痴情的归尘完成签到,获得积分10
33秒前
34秒前
39秒前
桐桐的应助被南宫雪采纳,获得10
42秒前
zzz完成签到,获得积分10
45秒前
科目三的应助被科研通管家采纳,获得10
50秒前
50秒前
充电宝的应助被科研通管家采纳,获得10
50秒前
null的应助被科研通管家采纳,获得10
50秒前
Orange的应助被科研通管家采纳,获得10
51秒前
英俊的铭的应助被科研通管家采纳,获得10
51秒前
54秒前
忧郁思远完成签到,获得积分10
55秒前
58秒前
teyr完成签到,获得积分10
1分钟前
机灵的夜梅完成签到,获得积分10
1分钟前
Pikachu完成签到,获得积分10
1分钟前
1分钟前
高大的紫萍完成签到,获得积分10
1分钟前
小祝没吃饱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
天真的音完成签到,获得积分10
1分钟前
陳源完成签到 ,获得积分10
1分钟前
ABC完成签到,获得积分10
1分钟前
芋头完成签到,获得积分10
2分钟前
2分钟前
复杂鸵鸟完成签到,获得积分10
2分钟前
2分钟前
Younger发布了新的文献求助10
2分钟前
2分钟前
忧郁依柔完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158694
求助须知:如何正确求助?哪些是违规求助? 9554462
关于积分的说明 21719198
捐赠科研通 7748257
什么是DOI,文献DOI怎么找? 3427070
关于科研通互助平台的介绍 2551949
邀请新用户注册赠送积分活动 2471308